Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy vs chemotherapy alone

Grade 3 to 4 rash · treatment of relapsed epithelial ovarian cancer

It is very uncertain whether EGFR tyrosine kinase inhibitor (TKI) plus chemotherapy changes toxicity: grade 3 or 4 rash compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor blockers for the treatment of ovarian cancer 2018 · Cochrane Headline outcomes only
RR 13.63 [0.78, 236.87]
1 study · 125 participants
Very low